Objective:To investigate the impact of using recombinant human endostatin on the treatment efficacy of middle and advanced stage non-small cell lung cancer(NSCLC).Method:A total of 98 patients with middle and advanced stage NSCLC admitted to the Department of Oncology Ⅲ,Yankuang New Mileage General Hospital from April 2020 to January 2023 were selected and randomly divided into the observation group and the control group,with 49 patients in each group.The control group received conventional chemotherapy for 3 cycles,while the observation group received additional Recombinant Human Endostatin therapy on the basis of the control group for 3 cycles.The treatment efficacy,serum levels of cytokeratin 19 fragment(Cyfra21-1),vascular endothelial growth factor(VEGF),and carcinoembryonic antigen(CEA)before treatment and after 3 cycles of treatment,as well as the quality of life(SF-36)scores before treatment and after 3 cycles of treatment were compared between the two groups.The incidence of adverse reactions was also observed and compared.Result:The total effective rate in the observation group was higher than that in the control group(P＜0.05).After 3 cycles of treatment,the serum levels of CEA,Cyfra21-1,and VEGF in both groups decreased,with lower levels in the observation group compared to the control group,the differences were statistically significant(P＜0.05).After 3 cycles of treatment,the quality of life scores in both groups increased compared to before treatment,with higher scores in the observation group compared to the control group,the differences were statistically significant(P＜0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups during the treatment period(P＞0.05).Conclusion:The use of Recombinant Human Endostatin as an adjuvant to conventional chemotherapy in the treatment of middle and advanced stage NSCLC helps reduce serum levels of CEA,Cyfra21-1,and VEGF while improving the quality of life without aggravating adverse reactions.
关键词
非小细胞肺癌/中晚期/重组人血管内皮抑制素/癌胚抗原/细胞角蛋白19片段/血管内皮生长因子
Key words
Non-small cell lung cancer/Middle and advanced stage/Recombinant Human Endostatin/Carcinoembryonic antigen/Cytokeratin 19 fragment/Vascular endothelial growth factor
维普
万方数据